RecruitingPhase 2NCT07694440

A Study of MZE782 in Adults With PKU

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults With Phenylketonuria (PKU)

Sponsor

Maze Therapeutics

Enrollment

38 participants

Start Date

Jun 23, 2026

Study Type

INTERVENTIONAL

Conditions

Phenylketonuria (PKU)

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MZE782, a drug called MZE782, and others for people with phenylketonuria (pku). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMZE782

Tablet, Low Dose

OTHERPlacebo

Tablet

DRUGMZE782

Tablet, High Dose

Locations(2)

Indiana University School of Medicine

Indianapolis, Indiana, United States

Clinic for Special Children

Gordonville, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07694440

Related Trials

A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)

NCT076727561 location

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

NCT0581367826 locations